Delving into the Latest Updates on Guselkumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Guselkumab (Genetical Recombination), Guselkumab (genetical recombination) (JAN), Guselkumab (USAN)

+ [8]

Target

IL-23p19

Action

inhibitors

Mechanism

IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [7]

Active Indication

Crohn's disease, active moderateCrohn's disease, active severeUlcerative colitis, active moderate+ [26]

Inactive Indication

Adenomatous Polyposis ColiCeliac DiseaseGeneralized Pustular Psoriasis+ [4]

Originator Organization

Janssen Global Services LLC

Active Organization

Janssen-Cilag International NVJanssen Scientific Affairs LLCJanssen Research & Development LLC

+ [11]

Inactive Organization

Janssen Cilag SpA

License Organization

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (13 Jul 2017),

Plaque psoriasis

RegulationPriority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Login to view timeline

Structure/Sequence

Sequence Code 9493545H

Source: *****

Sequence Code 9493571L

Source: *****

The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:
* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice?
* What is the safety profile and treatment persistence of IL-23 inhibitors in this population?
* Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.

Start Date01 May 2026

Sponsor / Collaborator-

NCT07444060

/ RecruitingNot ApplicableIIT

Efficacy of Guselkumab Versus Ustekinumab in Stricturing Crohn's Disease: A Multicenter, Prospective, Observational Cohort Study

This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through radiography or endoscopy. After the informed consent of the patients, comprehensive drug therapy with Guselkumab or Ustekinumab as the mainstay was performed. The basic information and medical history of the patients were collected, and the treatment process of the patients was followed up and recorded, and the drug regimen was adjusted according to the physician's experience and judgment. At different follow-up time points, blood, feces, tissue and other specimens of patients were collected according to the situation, and gastrointestinal endoscopy, imaging examination, laboratory index examination, self-assessment of subjects' symptoms, and nutritional risk screening were performed on the patients. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.

Start Date01 Mar 2026

Sponsor / Collaborator

The Second Affiliated Hospital Zhejiang University

NCT07245394

/ RecruitingNot ApplicableIIT

SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD

The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.
Patients will begin guselkumab based on their doctor's decision. If eligible, they may be invited to participate in the study, which involves monitoring symptoms, test results, and overall health over the course of one year.
Guselkumab will be given according to local medical guidelines. Doctors can adjust the treatment as needed, just like in routine care.
Researchers believe that switching to guselkumab may be as effective as other advanced treatments. For those who saw some improvement on ustekinumab but not enough, guselkumab may offer better symptom control-without worsening results on medical tests like endoscopy.
The goal is to explore better treatment options for people whose IBD has not been well controlled with current therapies.

Start Date29 Jan 2026

Sponsor / Collaborator

Janssen, Inc.

100 Clinical Results associated with Guselkumab

Login to view more data

100 Translational Medicine associated with Guselkumab

Login to view more data

100 Patents (Medical) associated with Guselkumab

Login to view more data

885

Literatures (Medical) associated with Guselkumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Article

Author: Zhdanava, Maryia ; Fitzgerald, Timothy ; Feldman, Steven R. ; Boonmak, Porpong ; Schwartzbein, Samuel ; Libchaber, Béatrice ; Pilon, Dominic

OBJECTIVE:

To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.

MATERIALS AND METHODS:

This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.

RESULTS:

At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).

CONCLUSIONS:

Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.

01 Mar 2026·JID innovations : skin science from molecules to population health

Assessing T-Cell Profile Shifts through IL-23 Inhibition by Guselkumab on Psoriasis

Article

Author: Morita, Akimichi ; Enomoto, Yuki ; Miyashiro, Masahiko ; Kanayama, Yoshifumi ; Masuda, Junya ; Watanabe, Oki ; Sugiura, Yukako ; Yamamoto, Aya ; Sakurai, Mai ; Mashiko, Shunya

Anti-IL-23 antibody therapies improve the underlying immunopathology of psoriasis. Immune profile dynamics after anti-IL-23 treatment and their association with the treatment response are unclear. Focusing on guselkumab, an anti-IL-23p19 antibody, we comprehensively analyzed immune cells, serum inflammatory molecules, and CD4⁺ T-cell transcriptomics to identify drug effects in psoriasis. Peripheral and lesional skin blood samples were collected from 24 biologic-naïve patients at baseline and after treatment with guselkumab. We conducted FACS analysis of regulatory T cells, resident memory T cells, and dendritic cells; measured serum cytokine and chemokine levels; and analyzed RNA-sequencing data for gene expression changes in peripheral CD4⁺ T cells. Guselkumab administration increased regulatory T cells and decreased resident memory T cells. Gene expression differences at baseline defined 2 groups on the basis of the treatment response: transcriptomic profile-based high responders and transcriptomic profile-based moderate responders. Expression of certain chemokines, such as CXCL1 and CXCL5, was higher in the moderate responders, suggesting their association with a lower treatment response. RNA-sequencing analysis revealed gene expression changes related to T helper 17 cells and regulatory T cell activity. We observed alterations in regulatory T cells and resident memory T cells in response to guselkumab treatment that may contribute to the long-term suppression of the IL-23-driven inflammatory pathology in psoriasis. Furthermore, baseline peripheral blood transcriptomic immune findings may predict therapeutic outcomes. The G-Grope trial was registered as jRCTs041200070 with the Japan Registry of Clinical Trials on December 8, 2020.

24 Feb 2026·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Intraclass switching of interleukin-23 inhibitors in psoriasis: effectiveness, patterns and predictors of response – a retrospective multicentre study in Italy

Article

Author: Trovato, Emanuele ; Lembo, Serena ; Megna, Matteo ; Manfredini, Marco ; Moretta, Gaia ; Burlando, Martina ; Balato, Anna ; Musumeci, Maria Letizia ; Carugno, Andrea ; Ribero, Simone ; Giunta, Alessandro ; Caldarola, Giacomo ; De Luca, Eleonora

Abstract:

Background:

Interleukin (IL)-23 inhibitors are highly effective therapies for psoriasis, but some patients may need to discontinue the treatment. Intraclass switching is a potential strategy, although data on its effectiveness remain limited.

Objectives:

To evaluate the patterns and effectiveness of intraclass switching among IL-23 inhibitors in a real-world setting.

Methods:

This retrospective, multicentre study included adult patients with plaque psoriasis who switched between IL-23 inhibitors. Clinical and demographic data were analysed, and univariable and multivariable analyses identified predictors of treatment response.

Results:

We analysed 116 patients (120 switches). Switching occurred from guselkumab (45.0%), tildrakizumab (44.2%) and risankizumab (10.8%), mainly due to secondary ineffectiveness (82.5%). Risankizumab was the most common post-switch agent (70.0%), followed by guselkumab (23.3%) and tildrakizumab (6.7%). Psoriasis Area and Severity Index 90% improvement (PASI 90) rates were 28.5% at week 16, 49.5% at week 36 and 60.7% at week 52. Fifteen patients (12.5%) withdrew from treatment, mainly due to lack of efficacy (10 patients, 67%) or adverse events (4 patients, 27%). Univariate analysis showed lower PASI 90 achievement in patients with psoriatic arthritis at weeks 16 after the switch (P = 0.02) and 36 (P = 0.02) and in those with body mass index (BMI) ≥ 25 kg m–2 at week 52 (P = 0.01). Patients switching from risankizumab had lower PASI 90 rates at weeks 16 (P = 0.04) and 36 (P = 0.03), while those switching to risankizumab had higher PASI 90 rates at week 16 (P = 0.02). Multivariate analysis confirmed BMI ≥ 25 kg m–2 was associated with reduced PASI 90 at weeks 36 (P = 0.04) and 52 (P = 0.04).

Conclusions:

Intraclass switching among IL-23 inhibitors is an effective strategy, with risankizumab emerging as the most favourable option.

301

News (Medical) associated with Guselkumab

20 Mar 2026

·www.pharmaceutical-technology.com

J&J wins FDA approval for Icotyde to enter psoriasis pill market

Analysis by GlobalData expects 2032 global sales for the drug will reach $4.4bn globally. Credit: PixelBiss/Shutterstock.com. The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s (J&J) Icotyde (icotrokinra) for the treatment of plaque psoriasis, marking the first US entry of an oral peptide in the indication. J&J’s treatment is approved for adults and paediatric patients aged 12 and older with moderate-to-severe forms of the disease. Patients who are candidates for systemic therapy or phototherapy will be eligible for Icotyde. Psoriasis is a chronic autoimmune condition causing skin cells to multiply rapidly, resulting in thick, itchy, scaly patches. Icotyde works by inhibiting interleukin-23 (IL-23), a protein that plays a key role in inflammation. Psoriasis affects more than 8 million people in the US. J&J’s pill was approved based on four Phase III studies that included 2,500 patients. Icotyde met all primary efficacy endpoints, helping patients achieve clearer skin and reducing psoriasis severity. The drug also performed well in head-to-head superiority studies against Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib). Sotyktu and AbbVie’s Skyrizi (risankizumab) currently dominate the plaque psoriasis market in the US. Sotyktu is an oral small molecule inhibitor that targets tyrosine kinase 2 (TYK2), while Skyrizi is AbbVie’s blockbuster injected monoclonal antibody that inhibits IL-23. The FDA’s approval for Icotyde means it is the only oral peptide that targets IL-23 in the plaque psoriasis US market. GlobalData analyst, Stephanie Ngan, commented: “Its strongest selling point is its biologic-like efficacy delivered in a once-daily oral pill, likely enabled by its macrocyclic design, and contrasts existing oral options. The competitive threat against Sotyktu is especially acute, given that Icotyde has demonstrated superiority over it in head-to-head trials.” “That being said, Icotyde does entail a higher treatment burden and daily commitment than biologics such as Skyrizi, which requires only 4 doses per year,” Ngan added. Icotyde will succeed J&J’s Stelara (ustekinumab), an IL-23 inhibitor approved for plaque psoriasis treatment that lost patent exclusivity in early 2025. J&J also has Tremfya (guselkumab) on the market in this indication, though like Skyrizi, the drug is injected. Leah Howard, CEO of the National Psoriasis Foundation, said: “The approval of a novel systemic therapy changes the conversation about treatment options for our community.” J&J is eying further inflammatory indications for its IL-23 inhibitor. These include active psoriatic arthritis studies ICONIC-PsA 1 (NCT06878404) and ICONIC-PsA 2 (NCT06807424); ICONIC-UC (NCT071196748) in moderately-to-severely active ulcerative colitis; and ICONIC-CD (NCT7196722) in moderately-to-severely active Crohn’s disease. Analysis by GlobalData, Pharmaceutical Technology’s parent company, forecasts a blockbuster for J&J’s drug, with 2032 sales expected to reach $4.4bn globally. Ngan stated: “Simultaneous approval of Icotyde for both adults and adolescents, rather than the traditional step-wise path from adults into paediatrics immediately casts a wider net for early uptake across a broader patient population.” J&J acquired global rights to Icotyde from Protagonist Therapeutics via a deal worth up to $990m in 2017. In late 2025, the Wall Street Journal (WSJ) reported the companies were in talks regarding a potential acquisition , though no update has been made public since. It will take some effort to displace Skyrizi’s dominance, however. Armed with a range of immunology indications, along with a strong adoption in inflammatory bowel disease (IBD), the drug has become a major revenue driver for AbbVie. In 2025, the injectable’s global sales reached $17.6bn, exceeding growth forecasts. Skyrizi’s performance has eased AbbVie’s dependency on Humira (adalimumab), which lost exclusivity in 2023 – the product was the world’s best-selling drug between 2012 and 2020.

Drug ApprovalPhase 3AcquisitionClinical ResultBiosimilar

18 Mar 2026

·www.fiercepharma.com

Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio

Sandoz has inked a deal with Korean biosimilars specialist Samsung Bioepis to commercialize up to five copycats, including a knockoff of Takeda's Entyvio. Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of Takeda’s Entyvio (vedolizumab), which is being developed by the South Korea-based biosimilars specialist. Switzerland-based Sandoz gains the right to commercialize the biosimilars around the world, with Samsung Bioepis retaining commercial rights in China, Hong Kong, Taiwan, Macau and its home country. Samsung Bioepis will continue to develop, manufacture and handle the regulatory submissions for the biosimilars. Financial terms of the partnership were not disclosed. The deal, which builds on the existing partnership of the companies, has the potential to expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets, the company said in a release. The growing pipeline of products will allow Sandoz to capture a “significant share” of the $320 billion biosimilar loss-of-exclusivity market opportunity in the next decade, the company added.The companies initially got together in 2023, with Sandoz gaining commercial rights to Samsung’s Pyzchiva (ustekinumab), which is a knockoff of Johnson & Johnson’s Stelara. Sandoz launched it in Europe in July 2024 and in the U.S. in February 2025. Three months ago, the companies also paired up on Epysqli (eculizumab), which is Samsung’s biosimilar version of AstraZeneca’s Soliris.With the most recent agreement, analysts from Jefferies credited Sandoz’s “commercial infrastructure” as key to its ability to attract partners. They also noted that the Samsung Bioepis arrangement provides Sandoz with “improved long-term visibility on both R&D productivity and future launch cadence.” Samsung Bioepis plans to expand its biosimilar portfolio by 20 products by 2030, the company said two months ago at the J.P. Morgan Healthcare Conference. In addition to its Entyvio copycat, the company said it will develop biosimilar versions of Regeneron and Sanofi’s Dupixent, Johnson & Johnson’s Tremfya, Daiichi Sankyo and AZ’s Enhertu, Roche’s Ocrevus and Eli Lilly’s Taltz.As for Samsung and Sandoz’s plan to sell their Entyvio knockoff, Takeda has said its regulatory protection on the ulcerative colitis and Crohn’s disease treatment extends into May 2026. But some patents on the drug expire in 2032, according to the company's most recent annual report (PDF).“Any biosimilar that seeks to launch prior to 2032 would need to address potential infringement and/or the validity of all relevant patents and therefore the exact timing of biosimilar entry is uncertain,” the Japanese company explained in the report.For the last three quarters of 2025, Takeda reported Entyvio worldwide sales were up by 7% at 744.5 billion Japanese yen ($4.98 billion), with U.S. sales accounting for 494.8 billion Japanese yen ($3.03 billion).

License out/inDrug ApprovalBiosimilar

18 Mar 2026

·endpoints.news

FDA approves J&J's psoriasis pill Icotyde with $5B+ peak sales potential

Johnson & Johnson secured an FDA approval on Wednesday for a psoriasis pill it expects to become a megablockbuster. Regulators gave the green light to icotrokinra, which will be branded as Icotyde, in patients 12 and older with moderate-to-severe plaque psoriasis. There was no immediate information on pricing, but J&J expects peak sales to surpass $5 billion annually if it gets approved in other immunologic diseases. As a once-daily oral option, Icotyde is expected to compete with established psoriasis drugs not just on efficacy but also convenience. Both Icotyde and AbbVie’s Skyrizi — the runaway market leader with more than $17 billion in sales last year — target IL-23. But Skyrizi is an injectable drug, given every 12 weeks. J&J’s Tremfya is also a psoriasis injectable. Icotyde has also shown effectiveness compared to Bristol Myers Squibb’s Sotyktu, another once-daily psoriasis pill targeting TYK2. Last September, J&J said its drug beat Sotyktu in two Phase 3 studies. Researchers are also testing Icotyde against another J&J drug, Stelara, an injectable that targets both IL-12 and IL-23. But J&J and its biotech partner Protagonist Therapeutics have work to do outside psoriasis to reach that $5 billion figure, most notably in inflammatory bowel diseases like ulcerative colitis and Crohn’s. Early results have been promising, with Icotyde succeeding in a Phase 2b UC study last year. The approval represents the first commercial product for Protagonist, though J&J will handle the launch and sales. Protagonist will get a $50 million milestone payment for the decision and can get up to another $580 million in biobucks, as well as royalty payments on sales between 6% and 10%. The FDA is expected to decide whether to approve another of Protagonist’s drugs, rusfertide — a rare blood disorder program partnered with Takeda — by August.

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Guselkumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10438	Guselkumab	L04AC16	DB11834

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Crohn's disease, active moderate	China	Janssen-Cilag International NV	20 Feb 2025
Crohn's disease, active severe	China	Janssen-Cilag International NV	20 Feb 2025
Ulcerative colitis, active moderate	United States	Janssen Biotech, Inc.	11 Sep 2024
Ulcerative colitis, active severe	United States	Janssen Biotech, Inc.	11 Sep 2024
Pustulosis of Palms and Soles	Japan	Janssen Pharmaceutical KK	21 Nov 2018
Colitis, Ulcerative	South Korea	Janssen Korea Ltd.	12 Apr 2018
Crohn Disease	South Korea	Janssen Korea Ltd.	12 Apr 2018
Keratoderma, Palmoplantar	South Korea	Janssen Korea Ltd.	12 Apr 2018
Erythrodermic psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Pustular psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Arthritis, Psoriatic	European Union	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Iceland	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Liechtenstein	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Norway	Janssen-Cilag International NV	10 Nov 2017
Plaque psoriasis	United States	Janssen Biotech, Inc.	13 Jul 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	NDA/BLA	United States	Johnson & Johnson	02 Dec 2024
Pediatric Crohn's Disease	Phase 3	Netherlands	Janssen Research & Development LLC	10 Jan 2023
Psoriasis of scalp	Phase 3	United States	Janssen Research & Development LLC	13 Jul 2022
Psoriasis of scalp	Phase 3	Canada	Janssen Research & Development LLC	13 Jul 2022
Inflammatory Bowel Diseases	Phase 3	Netherlands	Janssen Research & Development LLC	01 Jun 2022
Perianal fistula due to Crohn's disease	Phase 3	Spain	Janssen Research & Development LLC	19 Apr 2022
Neoplasms	Phase 3	United States	Janssen Research & Development LLC	24 Aug 2017
Neoplasms	Phase 3	Australia	Janssen Research & Development LLC	24 Aug 2017
Neoplasms	Phase 3	Canada	Janssen Research & Development LLC	24 Aug 2017
Neoplasms	Phase 3	Czechia	Janssen Research & Development LLC	24 Aug 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05272150 (VISIBLE, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Plaque psoriasis \| Psoriasis of scalp	205	Guselkumab 100 mg	oveyxehkwe(fnbfbminhu) = trkcsagjsr jgcvgelwnt (vpradcejmi ) View more	Positive	02 Mar 2026
NCT04033445 (QUASAR, Company_Website) Manual	Phase 2/3	Colitis, Ulcerative	-	TREMFYA	odnfwgtjjf(qqkmlyrxtp) = injarswmjw optvierqyu (xgoxmzdknm ) View more	Positive	21 Feb 2026
NCT04882098 (APEX, CTgov)	Phase 3	Arthritis, Psoriatic	1,054	Placebo+Guselkumab	zgxoxdnrdk = onkdrwvvtc qgwvnxuiqw (ukkupcujuw, jvmwfonmho - udyhxdobwj) View more	-	04 Feb 2026
NCT03796858 (COSMOS, Pubmed \| Rheumatol Ther)	Phase 3	Arthritis, Psoriatic	285	Guselkumab	xbdyuiaomv(tdmzktpqsq): HR = 1.29 (95.0% CI, 0.93 - 1.81) View more	Positive	23 Jan 2026
				Placebo
NCT05528510 (ASTRO, Pubmed \| Lancet Gastroenterol Hepatol)	Phase 3	Colitis, Ulcerative	418	Guselkumab 400/100 mg	inutcdpmbk(csttzwzhvp) = jnbdxoqszv tygqjbihmq (djxvkhjmju ) View more	Positive	01 Jan 2026
				Guselkumab 400/200 mg	inutcdpmbk(tetojcucfe) = qxqrxcrbjt atsguijldn (ilzzkvchbb ) View more
NCT05528510 (ASTRO, CTgov)	Phase 3	Colitis, Ulcerative	418	placebo+guselkumab (Placebo)	rffodjcbsr = ewjhsnyzyp rpovbvhedi (smyozaydon, fvrxothnmu - pfpdwumckb) View more	-	09 Dec 2025
				Guselkumab (Combined Guselkumab 400 mg)	rffodjcbsr = xqtyhagktm rpovbvhedi (smyozaydon, lqmswcmnmb - thrwoxeynh) View more
NCT04936308 (SOLSTICE, CTgov)	Phase 3	Salivary Gland Adenoma, Pleomorphic \| Neoplasms \| Arthritis, Psoriatic	453	Placebo+Guselkumab (Placebo Followed by Guselkumab 100 mg)	sgeltpcydz = boycwcwpzc vtvuitimio (xvrlchelqf, jnggdbovfn - iggaosydbz) View more	-	08 Dec 2025
				Guselkumab (Guselkumab 100 mg q8w)	sgeltpcydz = rsmbeyrcol vtvuitimio (xvrlchelqf, zjtnebwsmv - aufnwwoqfg) View more
NCT03158285 \| NCT03451851 (DISCOVER-1/-2, Pubmed \| Paediatr Drugs)	Phase 3	Psoriasis \| Arthritis, Psoriatic \| Juvenile Idiopathic Arthritis	1,589	Guselkumab (pediatric PsO)	ungxijfwha(nxvjyoxvyx) = iqettofvuf hvvkwauhig (wnlikgxxvx ) View more	Positive	28 Oct 2025
				Guselkumab (adult PsO)	ungxijfwha(nxvjyoxvyx) = dvgdaueqlp hvvkwauhig (wnlikgxxvx ) View more
NCT05197049 (GALAXI 3, PRNewswire) Manual	Phase 3	Crohn Disease	-	TREMFYA® 100 mg q8w	juuhxevqhv(vptvpehpmr) = rzemccovab qchztsfagx (htcsetowtx ) View more	Positive	27 Oct 2025
				TREMFYA® 200 mg q4w	juuhxevqhv(vptvpehpmr) = flqjdrdwya qchztsfagx (htcsetowtx ) View more
ACR2025	Not Applicable	Arthritis, Psoriatic	2,754	Guselkumab (biologic-naïve)	dksxozbqoi(yzhiyfeexx) = tlcnfrekbz hkxwxnvvws (rqdgdclbeg ) View more	Positive	24 Oct 2025
				SC Interleukin-17A Inhibitors (biologic-naïve)	dksxozbqoi(yzhiyfeexx) = xyaxibdoqu hkxwxnvvws (rqdgdclbeg ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data